Genprex Inc Stock Price, News & Analysis

Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data for Reqorsa® (quaratusugene ozeplasmid) at the 2025 AACR‑NCI‑EROTC conference in Boston on October 25, 2025. Studies show QO upregulates TUSC2 and induces apoptosis in ALK‑EML4 positive NSCLC models.

Key findings: QO alone and combined with alectinib reduced tumor volume by 79% in an NCI‑H2228 mouse model versus 60% for alectinib alone; QO increased caspase 3/7 activity, pro‑apoptotic markers, DNA fragmentation, and reduced colony formation. Results support a potential clinical trial pathway for REQORSA in ALK+ NSCLC.

Genprex (NASDAQ: GNPX) said collaborators will present positive preclinical data for Reqorsa® gene therapy (quaratusugene ozeplasmid) for ALK-EML4 positive non-small cell lung cancer at the 2025 AACR-NCI-EROTC conference in Boston.

The poster from the University of Michigan Rogel Cancer Center will be shown on October 25, 2025 (12:30–4:00 p.m. ET) and reports TUSC2 upregulation by Reqorsa inducing apoptosis in EML4-ALK bearing NSCLC in preclinical studies. Genprex cited a Sponsored Research Agreement from October 2024 with the University of Michigan and noted co-sponsorship by patient group ALK Positive. Laboratory data reported tumor-cell uptake of TUSC2 after Reqorsa treatment at 10–33x versus normal cells.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in three major conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10), the King Faisal Specialist Hospital & C3 Davos Healthcare Summit (September 8), and the Investor Summit Group Q3 Virtual Conference (September 16-17).

President and CEO Ryan Confer will deliver presentations highlighting Genprex's gene therapies for cancer and diabetes. Management will be available for one-on-one meetings with investors and conference participants at all events.

Genprex (NASDAQ: GNPX) has received significant patent allowances for its lead drug candidate Reqorsa® Gene Therapy in combination with immune checkpoint inhibitors. The U.S. Patent Office has allowed a patent for Reqorsa with PD-L1 antibodies, while the European Patent Office has allowed one for combination with PD-1 antibodies. Both patents extend until at least 2037.

The company's Acclaim-3 Phase 1/2 clinical trial combines Reqorsa with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC) patients. This trial has received both FDA Fast Track Designation and Orphan Drug Designation. Genprex has already secured similar patents in multiple countries including Korea, Japan, Mexico, Russia, and China.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has issued a stockholder letter highlighting its progress in oncology and diabetes programs. Under the leadership of CEO Ryan Confer, the company reports significant advancements in its clinical development initiatives, particularly in two ongoing lung cancer trials.

The company emphasizes its commitment to developing novel gene therapies for cancer and diabetes patients, with multiple milestones expected in the second half of 2025. Genprex maintains its focus on streamlined strategies to build company-wide value while advancing its clinical programs.

Genprex (NASDAQ: GNPX) presented positive preclinical research results for GPX-002, its diabetes gene therapy drug candidate, at the 2025 American Diabetes Association Scientific Sessions. The therapy demonstrated promising results in non-human primates (NHPs) with streptozotocin-induced diabetes.

The research showed that GPX-002, which uses recombinant adeno-associated virus (rAAV) to deliver Pdx1 and MafA genes, successfully converted alpha cells into insulin-secreting beta-like cells. The treated NHPs showed improved glucose tolerance and reduced insulin requirements one month post-infusion. Temporary immunosuppression for 3 months proved effective in preventing anti-viral immunity, with researchers now evaluating a 6-month immunosuppression period.

Genprex (NASDAQ: GNPX) presented positive preclinical data for GPX-002, their diabetes gene therapy candidate, at the 2025 ADA Scientific Sessions. The research showcased a novel non-viral lipid nanoparticle (LNP) delivery system for diabetes gene therapy, demonstrating successful transfection of pancreatic cells through biliary duct infusion. Two specific LNPs showed high efficiency in transfecting α- and β-cells in mouse Islets of Langerhans, with the ALX-184 LNP achieving 100 times more luciferase activity in the pancreas compared to other organs. This breakthrough approach could enable repeat dosing without requiring immunosuppression, potentially offering advantages over traditional AAV delivery methods in treating Type 1 Diabetes.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in the BIO 2025 International Convention from June 16-19, 2025, in Boston. Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will represent the company and conduct one-on-one meetings with industry groups to discuss Genprex's gene therapies for cancer and diabetes. The BIO International Convention is the largest biotech event globally, attracting 20,000 industry leaders. Interested parties can schedule meetings through the conference portal or by contacting Investor Relations at investors@genprex.com.

Genprex (NASDAQ: GNPX) will present the trial design of its Acclaim-3 Phase 1/2 clinical trial at the 2025 ASCO Annual Meeting. The trial evaluates Reqorsa® Gene Therapy in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC). The study aims to improve the current median progression-free survival of 2.6 months in ES-SCLC patients. The trial's Phase 2 portion, which began enrollment in December 2024, will include 50 patients and targets a median PFS of approximately 4.3 months. The presentation will take place on May 31, 2025, featuring research showing that TUSC2, a tumor suppressor gene, is decreased in 100% of SCLC patients and absent in 41% of cases. Preclinical studies demonstrated that the Reqorsa-Tecentriq combination significantly increased tumor cell killing compared to Tecentriq alone.